Trials / Completed
CompletedNCT00477113
TYSABRI Global Observational Program in Safety
TYGRIS: TYSABRI® Global Observational Program in Safety
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 2,207 (actual)
- Sponsor
- Biogen · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The Primary objective of this study is to determine the incidence and pattern of serious infections, malignancies, and other serious adverse events (SAE) in participants with multiple sclerosis (MS) treated with Tysabri (natalizumab).
Detailed description
The TYSABRI Global Observational Program in Safety (TYGRIS) is a safety observational cohort program designed to obtain long-term safety data in multiple sclerosis (MS) participants treated with natalizumab in a clinical practice setting in the United States or Canada.
Conditions
Timeline
- Start date
- 2007-01-01
- Primary completion
- 2015-05-01
- Completion
- 2015-05-01
- First posted
- 2007-05-22
- Last updated
- 2015-06-22
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00477113. Inclusion in this directory is not an endorsement.